SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.2% - What's Next?

Key Points

• SELLAS shares fell 8.2% to approximately $11.30 in mid-day trading, with volume down 64% versus the average session.
• Analyst views remain mixed: two analysts rate the stock “Buy,” one rates it “Sell,” and the consensus rating is “Hold” with a $10 average price target.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.05 per share, missing expectations by $0.01; institutional investors own 17.38% of its stock.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) shares dropped 8.2% during mid-day trading on Thursday. The stock traded as low as $11.51 and last traded at $11.2960. 2,914,079 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 8,026,477 shares. The stock had previously closed at $12.31.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SLS shares. Alliance Global Partners restated a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $10.00.

SELLAS Life Sciences Group Stock Down 7.8%

The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -53.90 and a beta of 2.52. The business's fifty day moving average is $12.37 and its 200 day moving average is $9.38.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Investors Weigh In On SELLAS Life Sciences Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nykredit A S bought a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at about $27,000. California State Teachers Retirement System raised its stake in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after buying an additional 1,709 shares during the period. Wealthfront Advisers LLC bought a new stake in SELLAS Life Sciences Group during the 1st quarter valued at $48,000. Principal Financial Group Inc. bought a new position in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $53,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of SELLAS Life Sciences Group by 82.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 19,777 shares of the company's stock worth $75,000 after buying an additional 8,944 shares in the last quarter. Institutional investors and hedge funds own 17.38% of the company's stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company's research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS's lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms' tumor 1 (WT1), a protein expressed in several types of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.